Breaking News
A new study shows melanoma forms resistance against the MAPK inhibitors that are commonly used to treat it, while at the same time actively suppressing the immune cells that would otherwise help eliminate it.
New clinical trial results show a personalized mRNA-based melanoma vaccine, intismeran, significantly reduces the risk of cancer recurrence or death within two years.
A new Phase II clinical trial shows HIPRA’s COVID-19 vaccine, BIMERVAX, administered as a booster dose after two previous doses with Comirnaty (Pfizer/BNTech), induces a broad immune response against multiple SARS-CoV-2 variants in adolescents.
A study has found females with autoimmune diseases are significantly more likely than males to have their autoimmune disease misdiagnosed as a psychiatric or psychosomatic condition.
A clinical trial at the Universidad Autónoma de Madrid (UAM) suggests that early administration of intravenous immune globulin (IVIG) could decrease the occurrence of new infections in transplanted individuals who present with hypogammaglobulinemia.
The Food and Drug Administration has approved atezolizumab in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III mismatch repair deficient colon cancer
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
BSTQ Podcast
Healthcare Marketplace News & Insights
The BioSupply Trends Quarterly (BSTQ) Podcast brings together healthcare professionals, researchers, innovators and advocates to explore the scientific, clinical and operational trends shaping the future of biotherapeutics, healthcare delivery and public health.
